News and Opinion

Preclinical Research Needs "Kaizen"

Published in Cancer

Go to the profile of Chi-Ping Day
Chi-Ping Day
Senior Research Biologist, National Cancer Institute, NIH
Preclinical Research Needs "Kaizen"
Like
Go to the profile of Evelina Satkevic
Go to the profile of Giuseppe Astori

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

Share with...

...or copy the link

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Nature News: Half of top cancer studies fail high-profile reproducibility effort

https://www.nature.com/articles/d41586-021-03691-0
The topic of this report is old- every a few years there were special issues in high-profile journals to discuss low replicatability in preclinical studies (both in vitro and in vivo) and call for systemically evaluating. Finally this is done and the results were published in eLife now. These studies confirm, again, the replicatability is low. OK, so what’s next?

I have worked on cancer modeling in mice for two decades, with hands-on experience in most of the time, so please allow me to provide a two-word answer from my experience: infrastructure and standardization. Institutions should invest to build teams and records for:

Mouse breeding and genotyping
Cell line maintenance and QC (such as STR assay, markers, sequencing results)
Therapeutic protocols
Endpoint analysis and criteria

Many institutes do not intend to invest in these infrastructures. Graduate students, postdocs, and research scientists are left alone to do all of these tasks, without help from and could not contribute to the infrastructures. When they leave, everything will be started all over again in Sisyphus style, and the publications are like castles built on sand. People on top of the pyramid try to use manpower to fill gap (“go counting these 500 slides and give me the statistics on Monday”), rather than investing in developing better methods.

To change the situation, we have to learn from "KAIZEN", a strategy employed by Japanese automobile industry, where employees at all levels of a company work together proactively to achieve regular, incremental improvements to the manufacturing process, preventing the tiny singularity events that accumulate to cause collapse. As the very first step, I believe we need to establish databases for research groups to upload published or unpublished preclinical study data, allowing meta-analysis for any given treatment, and examining the effects of different details (mouse strain, age, sex, etc.). This is step 1 in Edward Deming's approach!
Go to the profile of Chi-Ping Day
Chi-Ping Day
Senior Research Biologist, National Cancer Institute, NIH

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Sign In Register

Follow the Topic

Cancer Biology
Life Sciences > Biological Sciences > Cancer Biology
  • Nature Nature

    A weekly international journal publishing the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions.

    More about the journal

Related Collections

With Collections, you can get published faster and increase your visibility.

Carbon Dioxide Removal

In this cross-journal collection, we showcase articles that help with understanding how carbon dioxide removal can contribute to climate change mitigation.

Publishing Model: Hybrid

Deadline: Jan 16, 2027

Explore this Collection

Cancer Neuroscience: from mechanisms to therapy

With this collection, Nature Communications, Nature, Nature Cancer, Nature Neuroscience, Nature Progress Oncology, Nature Progress Brain Health, and Communications Biology invite submissions that aim to elucidate the molecular mechanisms underlying bidirectional cancer–nervous system interactions and their influence on the tumour microenvironment, as well as pre-clinical and clinical studies exploring potential therapeutic strategies to target neural–cancer interactions.

Publishing Model: Hybrid

Deadline: Jan 30, 2027

Explore this Collection

Recommended Content

Cookie Settings

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.

Further information can be found in our privacy policy.

Cookie Control

Customise your preferences for any tracking technology

The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.

Cookie policy Privacy policy
Always active, cannot be turned off
More information

These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.

More information

These trackers help us to deliver personalized marketing content and to operate, serve and track ads.

More information

These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.

More information

These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.

More information

These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.